How to transition patients to community-based bispecific antibody therapy
The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked about transitioning patients to community-based bispecific antibody therapy.
In this interview, Kumar discusses practical considerations for transitioning bispecific antibody therapy to community-based practice in patients with multiple myeloma. Kumar outlines strategies for monitoring and managing treatment-related toxicities, including cytokine release syndrome, neurological toxicities, cytopenias, and infections. Kumar also discusses patient education, supportive care, and the evolving role of less…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.